ARTIVA BIOTHERAPEUTICS INC (ARTV) — insider trading
Health Care · NASDAQ
ARTIVA BIOTHERAPEUTICS INC (ARTV) has 20 reported SEC Form 4 insider transactions in our data, including 12 open-market purchases and 5 open-market sales among the most recent 20 (latest 2026-06-26).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 1,876 | $8.98 | $16.8K | Form 4 |
| 2026-06-25 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 31,000 | $8.88 | $275.3K | Form 4 |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 124,893 | $8.89 | $1.11M | Form 4 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 15,414 | $8.99 | $138.6K | Form 4 |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 391,019 | $8.57 | $3.35M | Form 4 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 548,580 | $7.91 | $4.34M | Form 4 |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 103 | $7.00 | $721 | Form 4 |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 479,039 | $6.91 | $3.31M | Form 4 |
| 2026-05-19 | Aslan Fred | Director, Officer (Chief Executive Officer) | Open-market sale | 27,116 | $9.01 | $244.3K | Form 4 |
| 2026-05-19 | Banerjee Subhashis | Officer (Chief Medical Officer) | Open-market sale | 7,037 | $9.01 | $63.4K | Form 4 |
| 2026-05-19 | Bush Jennifer | Officer (COO, CLO, Compliance Officer) | Open-market sale | 8,790 | $9.01 | $79.2K | Form 4 |
| 2026-05-19 | Horan Christopher | Officer (Chief Tech Operations Officer) | Open-market sale | 7,002 | $9.01 | $63.1K | Form 4 |
| 2026-05-19 | Raymon Heather | Officer (SVP, Research and Development) | Open-market sale | 3,095 | $9.01 | $27.9K | Form 4 |
| 2026-05-18 | Miralles Gines Diego | Officer (President & Head of R&D) | Grant / award / vesting (derivative) | 232,500 | $0.00 | $0 | Form 4 |
| 2026-05-18 | Miralles Gines Diego | Officer (President & Head of R&D) | Grant / award / vesting | 77,500 | $0.00 | $0 | Form 4 |
| 2026-05-11 | GC Corp.; GC Cell Corp | 10% owner | Open-market purchase | 347,222 | $11.52 | $4.00M | Form 4 |
| 2026-05-11 | GC Corp.; GC Cell Corp | 10% owner | Open-market purchase | 1,085,069 | $11.52 | $12.50M | Form 4 |
| 2026-05-11 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase (derivative) | 2,170,138 | $11.52 | $25.00M | Form 4 |
| 2026-05-11 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; RA Capital Nexus Fund, L.P.; RA Capital Nexus Fund III, L.P.; Kolchinsky Peter; Shah Rajeev M. | Director, 10% owner | Open-market purchase | 6,510,416 | $11.52 | $75.00M | Form 4 |
| 2026-03-10 | Huston Thad Allen | Officer (Chief Financial Officer) | Grant / award / vesting | 220,000 | $0.00 | $0 | Form 4 |
Ask the chat about ARTV's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ARTIVA BIOTHERAPEUTICS INC (ARTV).
Last updated 2026-06-26 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.